By supporting and encouraging evidence-based access to gene therapy, payers and other segments of U.S. society will be positioned to benefit from future advancements and biopharmaceutical breakthrough...

Recent research suggests that the number of gene therapies on the market is likely to increase to over 60 by 2030. As rapid advancements in the field continue, here is what plan sponsors can expect to...

Gene therapies bring much-needed hope for treating rare conditions, but also concerns, especially around affordability. Learn about strategies plan sponsors can take to address these million-dollar me...